Candel Therapeutics Inc.

Candel Therapeutics Inc. is a biotechnology company specializing in oncolytic viral immunotherapy. Its primary function is to develop and commercialize innovative treatments designed to utilize the body's own immune system to combat cancer. Candel's proprietary technology platforms leverage genetically modified viruses to selectively infect and destroy cancer cells while sparing normal healthy tissues, thereby aiming to enhance the efficacy and specificity of cancer treatments. The company's focus primarily lies within the oncology sector, addressing critical unmet needs in treating a range of solid tumors. Through its advanced biotechnological approaches, Candel Therapeutics is engaged in a significant endeavor to transform cancer treatment modalities. By capitalizing on cutting-edge scientific research, the company holds a substantial role in the development of new cancer therapies, contributing to the broader biopharmaceutical industry. Based in the United States, Candel's work not only represents a promising frontier in personalized medicine but also underscores the growing significance of immunotherapy in modern healthcare.